uric acid/悪性腫瘍

BACKGROUND OF THE INVENTION Diseases caused by elevated levels of uric acid fall into two major categories: disorders caused by precipitation of uric acid crystals and diseases related to pathological effects of soluble uric acid. Gouty arthritis is the classic example of the former. Deposition of

BACKGROUND OF THE INVENTION Diseases caused by elevated levels of uric acid fall into two major categories: disorders caused by precipitation of uric acid crystals and diseases related to pathological effects of soluble uric acid. Gouty arthritis is the classic example of the former. Deposition of

BACKGROUND OF THE INVENTION Diseases caused by elevated levels of uric acid fall into two major categories: disorders caused by precipitation of uric acid crystals and diseases related to pathological effects of soluble uric acid. Gouty arthritis is the classic example of the former. Deposition of

BACKGROUND OF THE INVENTION Diseases caused by elevated levels of uric acid fall into two major categories: disorders caused by precipitation of uric acid crystals and diseases related to pathological effects of soluble uric acid. Gouty arthritis is the classic example of the former. Deposition of

BACKGROUND OF THE INVENTION This invention relates to a composition suitable for administration to mammalian hosts as a therapeutic formulation. More particularly, this invention relates to a combination therapy for free-radical bodily damage employing a lymphokine or cytotoxin such as tumor

FIELD OF THE INVENTION The present invention is directed to uricase modified with polyethylene glycol and to methods for treating number of different illnesses characterized by increased circulating uric acid levels. BACKGROUND OF THE INVENTION Uric acid is a product of purine metabolism in birds,

FIELD OF THE INVENTION The present invention relates to ancestral forms of mammalian uricases and uses thereof. BACKGROUND Uric acid, a natural breakdown product of DNA, RNA and ATP, is considered to be one of the most important antioxidants in blood plasma. Most mammals rely on uricase enzymes to

BACKGROUND OF THE INVENTION This invention relates to a composition suitable for administration to mammalian hosts as a therapeutic formulation. More particularly, this invention relates to a combination therapy for free-radical bodily damage employing a lymphokine or cytotoxin such as tumor

BACKGROUND OF THE INVENTION This invention relates to a composition suitable for administration to mammalian hosts as a therapeutic formulation. More particularly, this invention relates to a combination therapy for free-radical bodily damage employing a lymphokine or cytotoxin such as tumor

BACKGROUND OF THE INVENTION This invention is generally in the field of devices for the withdrawal and sensing of biological fluids, such as in the analysis of blood glucose levels. The extraction of analytes through the skin is critical to diabetic patients, who typically must measure blood glucose